A Study in Healthy People to Test Whether BI 730357 Influences the Amount of Caffeine, Warfarin, Omeprazole, and Midazolam in the Blood
Condition: Healthy
Intervention: Percoffedrinol®; Coumadin®; Antra MUPS®; Midazolam-ratiopharm®; BI 730357
Intervention description: Tablet; Tablet; Gastro-resistant tablet; Oral solution; Film-coated tablet
Intervention MeSH terms: Midazolam; Caffeine; Omeprazole; Warfarin
Phase: Phase 1
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Intervention model description: Two Periods (Period 1 and Period 2) for each participant.
Masking: None (Open Label)
Enrollment: 16.0
Sex: All
Minimum age: 18 Years
Maximum age: 55 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      The trial will be performed to assess the influence of BI 730357 on the pharmacokinetics of
      caffeine, warfarin, omeprazole and midazolam.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Healthy subjects according to the assessment of the investigator, as based on a
             complete medical history including a physical examination, vital signs (blood pressure
             (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests

          -  Age of 18 to 55 years (inclusive)

          -  Body mass index (BMI) of 18.5 to 29.9 kg/m2 (inclusive)

          -  Signed and dated written informed consent prior to admission to the study, in
             accordance with GCP and local legislation

          -  Either male subject, or female subject who meet any of the following criteria from at
             least 30 days before the first administration of trial medication until 30 days after
             trial completion:

               -  Use of non-hormonal intrauterine device plus condom for birth control

               -  A vasectomised sexual partner (vasectomy at least 1 year prior to enrolment)

               -  Surgically sterilised (including hysterectomy or bilateral tubal occlusion)

               -  Postmenopausal, defined as at least 1 year of spontaneous amenorrhea (in
                  questionable cases a blood sample with levels of follicle stimulating hormone
                  (FSH) above 40 U/L and estradiol below 30 ng/L is confirmatory)

        Exclusion Criteria:

          -  Any finding in the medical examination (including BP, PR, or ECG) deviating from
             normal and assessed as clinically relevant by the investigator

          -  Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg,
             diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the
             range of 45 to 90 bpm

          -  Any laboratory value outside the reference range that the investigator considers to be
             of clinical relevance

          -  Any evidence of a concomitant disease assessed as clinically relevant by the
             investigator

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological, or hormonal disorders

          -  Cholecystectomy or other surgery of the gastrointestinal tract (except appendectomy or
             simple hernia repair) that could interfere with the pharmacokinetics (PK) of the trial
             medication

          -  Diseases of the central nervous system (including but not limited to any kind of
             seizures or stroke), and other relevant neurological or psychiatric disorders

          -  History of relevant orthostatic hypotension, fainting spells, or blackouts Further
             inclusion exclusion criteria apply